Company Statements

April 27, 2023

NICE Recommends Expanded and Earlier Use of Kite CAR T-cell Therapy to Treat Certain Types of Blood Cancer

March 23, 2023

Kite’s Yescarta® First CAR T-cell Therapy to Receive Health Canada Authorization for Use as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

February 17, 2023

Christi Shaw to Depart Gilead and Kite Leadership End of Q1

January 26, 2023

Kite’s Yescarta® is First CAR T-cell Therapy Recommended for Routine Use in England, United Kingdom

January 10, 2023

Kite Expands Cell Therapy Manufacturing Operations in Maryland